Stockscreener 앱 받기
10.26
0.39%
-0.04
시간 외 거래:
10.26
전일 마감가:
$10.30
열려 있는:
$10.18
하루 거래량:
173.92K
Relative Volume:
0.52
시가총액:
$584.45M
수익:
-
순이익/손실:
$-69.79M
주가수익비율:
-8.4202
EPS:
-1.2185
순현금흐름:
$-54.55M
1주 성능:
+2.40%
1개월 성능:
-0.19%
6개월 성능:
+69.59%
1년 성능:
+112.42%
1일 변동 폭
$9.95
$10.45
1주일 범위
$9.87
$11.23
52주 변동 폭
$2.60
$11.23
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
10.26 | 586.73M | 0 | -69.79M | -54.55M | -1.2185 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 개시 | Jefferies | Buy |
| 2026-01-07 | 개시 | Oppenheimer | Outperform |
| 2025-12-03 | 개시 | Craig Hallum | Buy |
| 2025-12-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
Aug EndMonth: Will Design Therapeutics Inc benefit from green energy policies2026 Buyback Activity & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Design Therapeutics (DSGN) Receives a New Rating from a Top Analyst - The Globe and Mail
Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Jefferies Initiates Coverage On Design Therap... - Benzinga
Design Therapeutics (NASDAQ:DSGN) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage on Design Therapeutics With Buy Rating, $15 Price Target - marketscreener.com
Jefferies initiates coverage of Design Therapeutics (DSGN) with buy recommendation - MSN
Jefferies initiates Design Therapeutics stock with buy on drug potential - Investing.com
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program - Yahoo Finance
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% on Analyst Upgrade - Defense World
Design Therapeutics Inc devrait afficher une perte de 33 cents par actionEarnings AVANT-PAPIER - TradingView
[SCHEDULE 13D/A] Design Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Aug Breakouts: Can Design Therapeutics Inc expand its profit margins2026 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Piper Sandler reiterates Overweight on Design Therapeutics stock By Investing.com - Investing.com South Africa
RBC Capital raises Design Therapeutics stock price target on programs By Investing.com - Investing.com Australia
Design Therapeutics, Inc. 2025 Annual Report: GeneTAC® Platform, Genomic Medicine Strategy, and Pipeline Overview - Minichart
Royal Bank Of Canada Forecasts Strong Price Appreciation for Design Therapeutics (NASDAQ:DSGN) Stock - MarketBeat
RBC Capital raises Design Therapeutics stock price target on programs - Investing.com
Piper Sandler reiterates Overweight on Design Therapeutics stock - Investing.com
Design Therapeutics (NASDAQ:DSGN) Rare Disease Research In Nasdaq Today - Kalkine Media
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - Bitget
Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results - MarketBeat
Design Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
DSGN: GeneTACⓇ platform advances four programs for genetic diseases, with strong clinical and financial momentum - TradingView
Design Therapeutics Provides Update on Clinical Trials and Financial Position for 2025 - Quiver Quantitative
Design Therapeutics reports lower-than-expected Q4 net loss - TradingView
DSGN: Net loss rose to $69.8M in 2025 as R&D spending increased; $219.8M cash at year-end - TradingView
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
GeneTAC pipeline advances at Design Therapeutics (NASDAQ: DSGN) in FA, FECD, DM1 and HD - Stock Titan
DSGN: Clinical pipeline advanced, net loss $69.8M, cash reserves $219.8M fund operations into 2029 - TradingView
Design Therapeutics (Nasdaq: DSGN) widens 2025 loss but keeps $219.8M cash - Stock Titan
Three genetic disease trials push ahead at Design Therapeutics - Stock Titan
Stock Report: Is Design Therapeutics Inc currently under institutional pressureJuly 2025 Selloffs & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Design Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Earnings Risk: Will Design Therapeutics Inc benefit from green energy policies2025 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Antiverse Raises $9.3M Series A to Develop Antibodies for Undruggable Disease Targets and Announces Research Agreement with the Cystic Fibrosis Foundation - Business Wire
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday - MarketBeat
DSGNDesign Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference - Defense World
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Kymera Therapeutics (KYMR) and Argenx Se (ARGX) - The Globe and Mail
DSGN.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
DSGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - Barchart.com
Stock List: Research Stocks from Around the World - GuruFocus
DSGN: Clinical-stage genetic medicine programs in FA, FECD, and DM1 advance toward key data readouts - TradingView
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):